Laborie Medical Technologies, in Partnership with Urotronic Inc., Announces Completion of First Optilume® Procedures in the National Health Service (NHS), United Kingdom (UK)

in the October 2020, LABORIE and Urotronic Inc. (Urotronic), are entering into a diverse strategic partnership1. Urotronics, a Minnesota-based medical device company, currently conducting clinical studies in North America in support of the regulatory approval of Optilume®, a drug eluting balloon (DCB) technology for use in urethral strictures and benign prostatic hyperplasia (BPH) and in September 2020 received the CE mark for use in urethral strictures in Europe2.

After the successful procedures, Dr. Patel: “We are excited to be pioneering Optilume® Drug Coated Balloon technology to improve patient care in the treatment of urethral strictures. All procedures were carried out safely and went very well. Optilume offers a minimally invasive alternative with the potential for fewer relapses that is often seen with existing endoscopic treatment options. We look forward to closely monitoring our patient outcomes and developing this service as part of our treatment options for men with urethral stricture at Epsom Urology. “

In the UK, 16,000 men are hospitalized for urethral strictures each year and 12,000 of them require surgery, which costs £ 10 million annually3.4 . The condition blocks the way for urine to exit the body from the bladder and can lead to a painful, frustrating slowdown in the urinary system. Narrowing can be caused by infection, trauma, and other medical interventions that can injure the lining of the urethra and significantly affect patients’ quality of life. Multiple endoscopic treatments of the same stricture has been shown to progressively worsen the results. After a third endoscopic treatment, the failure rate approaches 75% after 6 months and reaches 100% two years after treatment5.

Optilume® DCB combines balloon dilatation to open the urethral stricture with the delivery of an antiproliferative drug to prevent the blockage from recurring. Published clinical follow-up data for two years6th emphasized that Optilume® DCB works both in opening blockages and in preventing the formation of scar tissue, which can develop rapidly as intended after traditional endoscopic surgery. This minimally invasive technology is expected to have a significant impact on the urological community, offering a new treatment option for urethral strictures that traditionally require major surgery or frequent endoscopic follow-up.

Professor. Watkin added, “We are encouraged by the early data from clinical trials of the Optilume® Drug Coated Balloon, and as a specialist urethral reconstruction center in the UK we believe we have a range of clinically effective treatment options and choices.” Adapt to patients and healthcare providers. This novel technology has the potential to positively influence the treatment of urethral strictures in the future, improve the quality of life for patients and potentially offer cost-effectiveness to our national health service. “

About Laborie Medical Technologies

Global headquarters in Portsmouth, New Hampshire, LABORIE is a global developer and manufacturer of innovative medical technologies and offers complete treatment pathways and market-leading solutions with its broad portfolio of diagnostic and therapeutic products and services in urology, gastroenterology, gynecology, obstetrics and neonatology. LABORIE is a Patricia Industries portfolio company. For more information, visit www.laborie.com.

About Urotronic Inc.

Urotronic, Inc., based in Plymouth, Minnesota, is a clinical stage medical device company currently conducting clinical trials to help commercialize its products worldwide. The Optilume® Drug eluting balloon technology offers an affordable, minimally invasive treatment option for men suffering from urinary tract diseases such as benign prostatic hyperplasia (BPH) and urethral stricture. The prevalence of BPH and lower urinary tract problems increases significantly with age. BPH affects 70% of men aged 60 to 69 years and 80% of men aged 70 years or older. The drug-coated balloon technology currently under development is causing a paradigm shift from the methods currently used by urologists to treat these diseases. For more information about Urotronic and our products, please visit us at urotronic.com.

About Patricia Industries

Patricia Industries is a long term business owner who invests in businesses and works to develop each business to its full potential. Patricia Industries is part of the industrial holding Investor AB, whose main owners are the Wallenberg Foundations.

About Investor AB

Investor AB, founded in 1916 by the Wallenberg family, is a committed owner of high-quality, global companies. We have a long-term investment perspective. Through our work on the Board of Management and through industrial experience, our network and our financial strength, we are continuously working to support our companies in remaining or becoming best-in-class.

REFERENCES

1. Cision PR Newswire October 8, 2020 https://www.prnewswire.com/news-releases/laborie-medical-technologies-enters-into-strategic-partnership-with-urotronic-301148859.html
2. Cision PR Newswire 23 September 2020 https://www.prnewswire.com/news-releases/new-treatment-for-urethral-strictures-optilume-receives-ce-approval-301136116.html
3. The interactive population pyramid. National Statistics Office. Available from: URL: http://www.statistics.gov.uk/populationestimates/flash_pyramid/default.htm.
4. Main procedures and interventions: 4-digit OPCS codes 2009-10. The NHS information center. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer?siteID=1937&categoryID=215
5. Steenkamp JW, Heyns CF, de Kock ML. Internal urethrotomy versus dilation for the treatment of male urethral strictures: a prospective, randomized comparison. J Urol. 1997 Jan; 157 (1): 98-101. PMID: 8976225.
6. Mann, RA, Virasoro, R., DeLong, JM, Estrella, RE, Pichardo, M., Rodríguez Lay, R., Espino, G., Roth, JD & Elliott, SP (2020). A drug eluting balloon treatment for urethral stricture: two-year results from the ROBUST I study. Journal of the Canadian Urological Association, fifteen(2). https://doi.org/10.5489/cuaj.6661

SOURCE Laborie Medical Technologies Inc.

Comments are closed.